Improving Hypertension Control in Vulnerable Populations Around the World
- 2 September 2023
- journal article
- review article
- Published by Springer Nature in Current Cardiology Reports
- Vol. 25 (10) , 1319-1326
Abstract
Purpose of Review This review aims to describe recent literature, guidelines, and approaches to reveal and reduce hypertension burden in disadvantaged populations. Hypertension is a major global health issue and the most potent risk factor for cardiovascular disease, morbidity, and mortality. It disproportionally affects vulnerable populations, including low-, middle-, and high-income countries. Specifically, the burden of hypertension is higher in US Black adults, and addressing social determinants of health is crucial for reducing disparities among vulnerable populations worldwide. Recent Findings Multifactorial approaches, including lifestyle modifications and combination drug therapy, are essential in managing hypertension. Community-based interventions, team-based care, and telehealth strategies can also improve hypertension control. Additionally, renal nerve denervation is a potential treatment for resistant hypertension. Summary Overall, to reduce the global hypertension burden among vulnerable populations, emphasis should be placed on equitable healthcare access and application of evidence-based medicine.Keywords
This publication has 41 references indexed in Scilit:
- Hypertension in older adults: Assessment, management, and challengesClinical Cardiology, 2019
- Adherence in HypertensionCirculation Research, 2019
- Uncontrolled Hypertension in Black MenCirculation, 2019
- Association of Clinical and Social Factors With Excess Hypertension Risk in Black Compared With White US AdultsJAMA, 2018
- Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patientsHeart, 2018
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice GuidelinesHypertension, 2018
- A Cluster-Randomized Trial of Blood-Pressure Reduction in Black BarbershopsNew England Journal of Medicine, 2018
- Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant HypertensionHypertension, 2018
- Medication adherence and beliefs about medication in elderly patients living alone with chronic diseasesPatient Preference and Adherence, 2018
- Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trialThe Lancet, 2015